- Home
- MLTX vs BLKB Comparison
MLTX vs BLKB Comparison
Compare MLTX & BLKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MLTX | BLKB |
|---|---|---|
| Founded | 2021 | 1981 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2020 | 2004 |
Fundamental Metrics
Financial Performance| Metric | MLTX | BLKB |
|---|---|---|
| Price | $18.46 | $42.60 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 12 | 3 |
| Target Price | $27.50 | ★ $50.00 |
| AVG Volume (30 Days) | ★ 1.1M | 681.0K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 142.32 |
| EPS | N/A | ★ 1.46 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.26 |
| Revenue Next Year | N/A | $4.25 |
| P/E Ratio | ★ N/A | $27.29 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.95 | $25.58 |
| 52 Week High | $62.75 | $70.71 |
Technical Indicators
Market Signals| Indicator | MLTX | BLKB |
|---|---|---|
| Relative Strength Index (RSI) | 45.13 | 72.18 |
| Support Level | $15.54 | $34.65 |
| Resistance Level | $19.24 | $63.74 |
| Average True Range (ATR) | 0.98 | 2.36 |
| MACD | -0.15 | 1.10 |
| Stochastic Oscillator | 5.17 | 78.44 |
Price Performance
Historical ComparisonAbout MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
About BLKB Blackbaud Inc.
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.